Back to top

Latest News

Photo of lady at desk on laptop
19 August 2019

Meeting the needs of people living with MS, their families and carers

Released today (Monday 19/8/19) a Report of the key results of a study into the needs of people living with MS, their families and carers.

A big thank you to all those who participated in this important project!

MS Australia releases findings of...
30 July 2019

Oceans of Hope announce New Zealand return and invitation to Aussie sailors with MS

A recent announcement from the Oceans of Hope team:

We are pleased to announce that Oceans of Hope UK will be returning to New Zealand in 2019. We have been working with our friends at MSNZ and ...

cup drink hand
24 July 2019

Communication with your Carer: How to set up Great Expectations

Old patterns are hard to break, and if you leave things too long, it can feel too awkward to bring them up.

Even when someone is a paid professional health care worker doing their job, it can be hard to approach them objectively, dispassionately and unapologetically to ask...

jennifer Holliday
25 June 2019

Legendary Tony & Grammy Award-winning Broadway star with MS to perform in Sydney

The original Dreamgirl and Broadway icon…Tony and Grammy Award Winning…Jennifer Holliday is set to make her Australian Debut!

Famous for her huge hit and show stopping performance of,...

One day to go
29 May 2019

World MS Day 2019

World MS Day 2019 on Thursday 30 May is an annual global day to raise awareness about multiple sclerosis (MS) and the needs of people living with the condition.

This year’s theme,...

2 May 2019

TGA approval of Gilenya® (fingolimod) as first licensed oral treatment for paediatric MS

On Wednesday 1 May 2019, Novartis announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis.

The registration makes Gilenya the first licenced...

15 April 2019

Alemtuzumab (Lemtrada®) under safety review by European Medicines Agency

Alemtuzumab (Lemtrada®), one of the approved treatments for relapsing MS in Australia, is being reviewed as a first line therapy by regulatory bodies overseas. The European Medicines Agency (EMA) has started a safety review of alemtuzumab based on new reports overseas of rare but...

Budget 2019
5 April 2019

BUDGET 2019 – Both parties set the scene for the Federal Election

As many commentators have already said, this year’s Federal Budget is unusual. More than a month early, it marks the beginning of an election campaign, rather than setting out a national economic plan, with the Federal Election 2019 date to be announced shortly.

For people living with MS...

5 April 2019


MS Australia (MSA) welcomes today’s announcement by the Prime Minister, of the Royal Commission into Disability and his commitment, dedication and recognition of the challenges faced by people affected by multiple sclerosis (MS).

It’s important that this inquiry develops a fuller picture...

29 March 2019

Have your say! - Nationwide research project launched

MS Australia is conducting a landmark, nationwide ‘Consumer Insights’ investigation.
This project consists of two online surveys designed to understand the needs of both...
Oceans of Hope
28 February 2019

Rediscovering hope and optimism aboard the Oceans of Hope

A research study titled, “”I can do more than I thought I could”: exploring the online blogs from the Sailing Sclerosis Oceans of Hope journey”, by researchers in the Faculty of Education at Monash University, Australia, was recently published in the international journal,...